Genetic variants of programmed cell death 1 are associated with HBV infection and liver disease progression
- PMID: 33833369
- PMCID: PMC8032722
- DOI: 10.1038/s41598-021-87537-9
Genetic variants of programmed cell death 1 are associated with HBV infection and liver disease progression
Erratum in
-
Author Correction: Genetic variants of programmed cell death 1 are associated with HBV infection and liver disease progression.Sci Rep. 2022 Feb 1;12(1):2034. doi: 10.1038/s41598-022-06068-z. Sci Rep. 2022. PMID: 35105917 Free PMC article. No abstract available.
Abstract
The inhibitory effects of programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) modulates T-cell depletion. T-cell depletion is one of the key mechanisms of hepatitis B virus (HBV) persistence, in particular liver disease progression and the development of hepatocellular carcinoma (HCC). This case-control study aimed to understand the significance of PD-1 polymorphisms (PD-1.5 and PD-1.9) association with HBV infection risk and HBV-induced liver disease progression. Genotyping of PD-1.5 and PD-1.9 variants was performed by direct Sanger sequencing in 682 HBV-infected patients including chronic hepatitis (CHB, n = 193), liver cirrhosis (LC, n = 183), hepatocellular carcinoma (HCC, n = 306) and 283 healthy controls (HC). To analyze the association of PD-1 variants with liver disease progression, a binary logistic regression, adjusted for age and gender, was performed using different genetic models. The PD-1.9 T allele and PD-1.9 TT genotype are significantly associated with increased risk of LC, HCC, and LC + HCC. The frequencies of PD-1.5 TT genotype and PD-1.5 T allele are significantly higher in HCC compared to LC patients. The haplotype CT (PD-1.5 C and PD-1.9 T) was significantly associated with increased risk of LC, HCC, and LC + HCC. In addition, the TC (PD-1.5 T and PD-1.9 C) haplotype was associated with the risk of HCC compared to non-HCC. The PD-1.5 CC, PD-1.9 TT, genotype, and the CC (PD-1.5 C and PD-1.9) haplotype are associated with unfavorable laboratory parameters in chronic hepatitis B patients. PD-1.5 and PD1.9 are useful prognostic predictors for HBV infection risk and liver disease progression.
Conflict of interest statement
The authors declare no competing interests.
Figures




Similar articles
-
Association of PD-L1 gene polymorphisms and circulating sPD-L1 levels with HBV infection susceptibility and related liver disease progression.Gene. 2022 Jan 5;806:145935. doi: 10.1016/j.gene.2021.145935. Epub 2021 Aug 31. Gene. 2022. PMID: 34478821
-
Circulating level of sPD-1 and PD-1 genetic variants are associated with hepatitis B infection and related liver disease progression.Int J Infect Dis. 2022 Feb;115:229-236. doi: 10.1016/j.ijid.2021.12.325. Epub 2021 Dec 12. Int J Infect Dis. 2022. PMID: 34910956
-
Impacts of human leukocyte antigen DQ genetic polymorphisms and their interactions with hepatitis B virus mutations on the risks of viral persistence, liver cirrhosis, and hepatocellular carcinoma.Infect Genet Evol. 2014 Dec;28:201-9. doi: 10.1016/j.meegid.2014.09.032. Epub 2014 Oct 2. Infect Genet Evol. 2014. PMID: 25281206
-
Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.Front Immunol. 2020 May 28;11:1037. doi: 10.3389/fimmu.2020.01037. eCollection 2020. Front Immunol. 2020. PMID: 32547550 Free PMC article. Review.
-
Harnessing CD8+ T cell dynamics in hepatitis B virus-associated liver diseases: Insights, therapies and future directions.Clin Transl Med. 2024 Jul;14(7):e1731. doi: 10.1002/ctm2.1731. Clin Transl Med. 2024. PMID: 38935536 Free PMC article. Review.
Cited by
-
Analysis of angiogenesis-related subtypes of hepatocellular carcinoma and tumor microenvironment infiltration feature in hepatocellular carcinoma.Clin Transl Oncol. 2023 Jul;25(7):2099-2115. doi: 10.1007/s12094-023-03084-x. Epub 2023 Jan 28. Clin Transl Oncol. 2023. PMID: 36708372
References
-
- WHO. Global Hepatitis Report, 2017 (2017).
-
- Liang, X. et al. Epidemiological serosurvey of hepatitis B in China—Declining HBV prevalence due to hepatitis B vaccination. Vaccine.27, 6550–6557. https://www.ncbi.nlm.nih.gov/pubmed/19729084 (2009). - PubMed
-
- Chisari, F. V. & Ferrari, C. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol.13, 29–60. http://www.ncbi.nlm.nih.gov/pubmed/7612225 (1995). - PubMed
-
- Chang, J. J. & Lewin, S. R. Immunopathogenesis of hepatitis B virus infection. Immunol. Cell Biol.85, 16–23. http://www.ncbi.nlm.nih.gov/pubmed/17130898 (2007). - PubMed
-
- Rehermann, B. & Nascimbeni, M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat. Rev. Immunol.5, 215–229. http://www.ncbi.nlm.nih.gov/pubmed/15738952 (2005). - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials